N-3 long-chain PUFA supplementation prevents high fat diet induced mouse liver steatosis and inflammation in relation to PPAR-α upregulation and NF-κB DNA binding abrogation

Molecular Nutrition and Food Research

Volumn 58, Issue 6, 2014, Pages 1333-1341

  Tapia, Gladys ^a   Valenzuela, Rodrigo ^a   Espinosa, Alejandra ^a   Romanque, Pamela ^a,b   Dossi, Camila ^a   Gonzalez Mañán, Daniel ^a   Videla, Luis A ^a   D'Espessailles, Amanda ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD DIEGO PORTALES   (Chile)

Author keywords

High fat diet; Liver steatosis; n 3 long chain PUFA; Nuclear factor B; Peroxisome proliferator activated receptor alpha

Indexed keywords

ACYL COENZYME A OXIDASE; DNA BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; C57BL MOUSE; DIET SUPPLEMENTATION; ENZYMOLOGY; FATTY LIVER; GENETICS; INFLAMMATION; LIPID DIET; LIVER; MALE; METABOLISM; MOUSE; ORGAN SIZE; UPREGULATION;

ACYL-COA OXIDASE; ANIMALS; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; DNA-BINDING PROTEINS; FATTY ACIDS, OMEGA-3; FATTY LIVER; INFLAMMATION; INTERLEUKIN-1BETA; LIVER; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; ORGAN SIZE; PPAR ALPHA; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84901940803     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300458     Document Type: Article

References (57)

1. Bellentani, S, Marino, M., Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol. 2009, 8, S4-S8.
2. Alberti, K. G., Zimmet, P., Shaw, J., IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005, 366, 1059-1062.
3. Poudyal, H., Panchal, S. K., Diwan, V., Brown, L., Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action. Prog. Lipid Res. 2011, 50, 372-387.
4. Musso, G., Gambino, R., Cassader, M., Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 2009, 48, 1-26.
5. Aronis, A., Madar, Z., Tirosh, O., Mechanism underlying oxidative stress-mediated lipotoxicity: exposure of J774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis. Free Radic. Biol. Med. 2005, 38, 1221-1230.
6. Videla, L. A., Rodrigo, R., Araya, J., Poniachik, J., Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol. Med. 2006, 12, 555-558.
7. Araya, J., Rodrigo, R., Videla, L. A., Thielemann, L. et al., Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci. 2004, 106, 635-643.
8. Araya, J., Rodrigo, R., Pettinelli, P., Araya, A. V. et al., Decreased liver fatty acid Δ-6 and Δ-5 desaturase activity in obese patients. Obesity 2010, 18, 1460-1463.
9. Brenner, R. R., Hormonal modulation of Δ6 and Δ5 desaturases: case of diabetes. Prostaglandins Leukot. Essent. Fatty Acids 2003, 68, 151-162.
10. Warensjö, E., Sundström, J., Vessby, B., Cederholm, T. et al., Markers of dietary fat quality and fatty acid desaturation as predictors of total and cardiovascular mortality: a population-based prospective study. Am J Clin Nutr. 2008, 88, 203-209.
11. Zhou, Y. E., Kubow, S., Dewailly, E., Julien, P., Egeland, G. M., Decreased activity of desaturase 5 in association with obesity and insulin resistance aggravates declining long-chain n-3 fatty acid status in Cree undergoing dietary transition. Br. J. Nutr. 2009, 102, 888-894.
12. Delarue, J., LeFoll, C., Corporeau, C., Lucas, D., N-3 long-chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity? Rep. Nutr. Develop. 2004, 44, 289-299.
13. Martinelli, N., Girelli, D., Malerba, G., Guarini, P. et al., FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linolenic acid are associated with inflammation and coronary artery disease. Am. J. Clin. Nutr. 2008, 88, 941-949.
14. Simopoulos, A. P., The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp. Biol. Med. 2008, 233, 674-688.
15. Valenzuela, R., Videla, L. A., The importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity. Food Funct. 2011, 2, 644-648.
16. Kim, W., McMurray, D. N., Chapkin, R. S., N-3 polyunsaturated fatty acids: physiological relevance of dose. Prostaglandins Leukot. Essent. Fatty Acids 2010, 82, 155-158.
17. Clarke, S. D., The multi-dimensional regulation of gene expression by fatty acids: polyunsaturated fats as nutrient sensors. Curr. Opin. Lipidol. 2004, 15, 13-18.
18. Goto, T., Kim, Y.-I., Takahashi, N., Kawada, T., Natural compounds regulate energy metabolism by the modulating activity of lipid-sensing nuclear receptors. Mol. Nutr. Food Res. 2013, 57, 20-33.
19. Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W. et al., Peroxisome proliferator-activated receptor-alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 1999, 274, 32048-32054.
20. Brunt, E. M., Janney, C. G., Di Biscegle, A. M., Neuschwander-Tetri, B. A., Bacon, B. R., Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999, 94, 2467-74.
21. Laemmli, U. K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227, 680-685.
22. Towbin, H., Staehlin, T., Gordon, J., Electroforetic transfer of proteins from polyacrilamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 1979, 76, 4350-4354.
23. Videla, L. A., Pettinelli, P., Misregulation of PPAR functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity. PPAR Res. 2012, 107434 . DOI:10.1155/2012/107434.
24. Leonarduzzi, G., Sottero, B., Testa, G., Poli, G., New insights into redox-modulated cell signaling. Curr. Pharmt. Design 2011, 17, 3994-4006.
25. Brigelius-Flohé R., Flohé L., Basic principles and emerging concepts in the redox control of transcription factors. Antioxid. Redox Signal. 2011, 15, 2335-2381.
26. Valenzuela, R., Espinosa, A., González-Mañán, D., D'Espessailles, A. et al., N-3 long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis. PLoS One 2012, 7, e46400.
27. Pettinelli, P., del Pozo, T., Araya, J., Rodrigo, R. et al., Enhancement in liver SREBP-1c/PPARα ratio and steatosis in obese patients: correlation with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim. Biophys. Acta 2009, 1792, 1080-1086.
28. Naitoh, R., Miyawaki, K., Harada, N., Mizunoya, W. et al., Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice. Biochem. Biophys. Res. Commun. 2008, 376, 21-25.
29. Pagano, C., Soardo, G., Esposito, W., Fallo, F. et al., Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur. J. Endocrinol. 2005, 152, 113-118.
30. Pettinelli, P., Videla, L. A., Up-regulation of PPAR-γ mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J. Clin. Endocrinol. Metab. 2011, 96, 1424-1430.
31. Czaja, M. J., Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology 2004, 40, 19-22.
32. Kadowaki, T., Yamauchi, T., Kubota, N., The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett. 2008, 582, 74-80.
33. Yoon, M. J., Lee, G. Y., Chung, J. J., Ahn, Y.-H. et al., Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor α. Diabetes 2006, 55, 2562-2570.
34. Kersten, S., Desvergne, B., Wahli, W., Roles of PPARs in health and disease. Nature 2000, 405, 421-424.
35. Ribeiro, P. S., Cortez-Pinto, H., Solá, S., Castro, R. E. et al., Hepatocyte apoptosis, expression of death receptors, and activation of NF-κB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am. J. Gastroenterol. 2004, 99, 1708-1717.
36. Videla, L. A., Tapia, G., Rodrigo, R., Pettinelli, P. et al., Liver NF-κB and AP-1 DNA binding in obese patients. Obesity 2009, 17, 973-979.
37. Gloire, G., Legrand-Poels, S., Piette, J., NF-κB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 2006, 72, 1493-1505.
38. Videla, L. A., Liver NF-κB and AP-1 activation and PPAR-α expression are negatively correlated in obese patients: pro-inflammatory implications. Clin. Nutr. 2010, 29, 687-688.
39. Zúñiga, J., Cancino, M., Medina, F., Varela, P. et al., N-3 PUFA supplementation triggers PPAR-α activation and PPA-α/NF-κB interaction: anti-inflammatory implications in liver ischemia-reperfusion injury. PLoS One 2011, 6, e28502.
40. González-Périz, A., Horrillo, R., Ferré, N., Gronert, K. et al., Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω-3 fatty acids: a role for resolvins and protectins. FASEB J. 2009, 23, 1946-1957.
41. Houstis, N., Rosen, E. D., Lander, E. S., Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440, 944-948.
42. Oster, R. T., Tishinsky, J. M., Yuan, Z., Robinson, L. E., Docosahexaenoic acid increases cellular adiponectin mRNA and secreted adiponectin protein, as well as PPARγ mRNA, in 3T3-L1 adipocytes. Appl. Physiol. Nutr. Metab. 2010, 35, 783-789.
43. Deminice, R., da Silva, R. P., Lamarre, S. G., Brown, C. et al., Creatine supplementation prevents the accumulation of fat in the livers of rats fed a high-fat diet. J. Nutr. 2011, 141, 1799-1804.
44. Lombardo, Y. B., Chicco, A. G., Effects of dietary polyunsaturated fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J. Nutr. Biochem. 2006, 17, 1-13.
45. de Roos, B., Mavrommatis, Y., Brouwer, I. A., Long-chain polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. Br. J. Pharmacol. 2009, 158, 413-428.
46. Ye, D., Zhang, D., Oltman, C., Dellsperger, K. et al., Cytochrome P450 epoxygenase metabolites of docosahexanoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J. Pharmacol. Exp. Ther. 2002, 303, 768-776.
47. Hong, S., Gronert, K., Devchand, P. R., Moussignac, R. I. et al., Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids and anti-inflammation. J. Biol. Chem. 2003, 278, 14677-14687.
48. Gao, L., Wang, J., Sekkar, K. R., Yin, H. et al., Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Culling3. J. Biol. Chem. 2007, 2529-2537.
49. Fernández, V., Tapia, G., Videla, L. A., Recent advances in liver preconditioning: thyroid hormone, n-3 long-chain polyunsaturated fatty acids and iron. World J. Hepatol. 2012, 4, 119-128.
50. Delerive, P., Gervois, P., Fruchart, J.-C., Staels, B., Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of PPARα activators. J. Biol. Chem. 2000, 275, 36703-36707.
51. Calder, P. C., Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75, 197-202.
52. Spadaro, L., Magliocco, O., Spampinato, D., Piro, S. et al., Effects of polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig. Liver Dis. 2008, 40, 194-199.
53. Zhu, F. S., Liu, S., Chen, X. M., Huang, Z. G. et al., Effects of polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipemia. World J Gastroenterol. 2008, 14, 6395-6400.
54. Hatzitolios, A., Savopoulos, C., Lazaraki, G., Sidiropoulos, I. et al., Efficacy of omega-3 fatty acids, atorvastatin, and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J. Gatroenterol. 2004, 23, 131-134.
55. Tanaka, N., Sano, K., Horiuchi, A., Tanaka, E. et al., Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2008, 42, 413-418.
56. Nobili, V., Bedogni, G., Alisi, A., Pietrobattista, A. et al., Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomized controlled clinical trial. Arch. Dis. Child 2011, 96, 350-353.
57. Shapiro, H., Tehilla, M., Attal-Singer, J., Bruck, R. et al., The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic disease. Clin. Nutr. 2011, 30, 6-19.